CD4 + T cells induced from human iPSCs (iCD4 + T cells) offer a therapeutic opportunity for overcoming immune pathologies arising from hematopoietic stem cell transplantation. However, most iCD4 + T cells are conventional helper T cells, which secrete inflammatory cytokines. We induced high-level expression of FOXP3, a master transcription factor of regulatory T cells, in iCD4 + T cells. Human iPSC-derived, FOXP3-induced CD4 + T (iCD4 + Treg-like) cells did not secrete inflammatory cytokines upon activation. Moreover, they showed demethylation of the Treg-specific demethylation region, suggesting successful conversion to immunosuppressive iCD4 + Treg-like cells. We further assessed these iCD4 + Treg-like cells for CAR-mediated immunosuppressive ability. HLA-A2 CAR-transduced iCD4 + Treg-like cells inhibited CD8 + cytotoxic T cell (CTL) division in a mixed lymphocyte reaction assay with A2 + allogeneic CTLs and suppressed xenogeneic graft-versus-host disease (GVHD) in NSG mice treated with A2 + human PBMCs. In most cases, these cells suppressed the xenogeneic GvHD progression as much as natural CD25 + CD127 - Tregs did.
Competing Interests: Declaration of interests S.K. is a director and shareholder at Shinobi Tx and received research funding from Shinobi Tx, Takeda Pharmaceutical, and Astellas. H.K received research funding from Chugai, Kyowa Kirin, Zenyaku Kogyo, Sumitomo Pharma, Eisai, Daiichi Sankyo, Otsuka Pharmaceutical, Perseus Proteomics, CURED, Astellas Pharma, Asahi Kasei, AbbVie, Nippon Shinyaku, JCR Pharmaceuticals, and Takeda Pharmaceutical. S.K. has patent applications related to the research (patent no. WO/2023/182328). T. Sato., T. Shinohara., K.K., A.M., K.N., M.S., and Y.K. are employees of Takeda Pharmaceutical Co. Ltd.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)